COVID-19 is associated with a high risk of thrombotic complications, which contribute to the high mortality rate. Limited data is yet available on systemic thromboembolism and the value of anticoagulation regimens. Prof. Yutao Guo (Chinese PLA General Hospital, China) presented the study that investigated the prevalence of systemic and venous thromboembolism, as well as major bleeding and mortality, in relation to underlying risk factors and the impact of anticoagulation use in hospitalised patients with COVID-19.
The study enrolled 1,125 patients with COVID-19 admitted to Union Hospital, Wuhan, China. Half of the participants (49.9%) were male and mean age was 58 years (36.3% were >65 years). They were followed for a mean of 21 days. Of the participants, 33 (2.9%) underwent surgery, and 249 patients (22.1%) received anticoagulants, of whom 7.7% received oral anticoagulants, 18.6% parenteral anticoagulants, and 4.2% oral plus parenteral anticoagulants.
Thromboembolic and bleeding events
There were 82 thromboembolism events (7.3%; 37 systemic and 45 venous events), 128 major bleeding events (11.4%), and 91 deaths (8.1%). About 25 patients (30%) with thromboembolism also suffered bleeding events. Age was an independent risk factor for thromboembolism, bleeding events, and death (all P<0.05).
After adjusting for the severity of COVID-19 infection, comorbidities, surgery, and use of antiviral drugs, immunomodulators, Chinese herbs, and antithrombotic drugs:
- low lymphocyte counts (HR 1.03; P=0.01) and surgery (HR 2.80; P=0.03) independently predicted the risk for major bleeding;
- liver dysfunction (HR 4.13; P=0.02) was an independent risk factor for patients with both thromboembolism and bleeding events; and
- AF or irregular rhythm increased the risk for systemic thromboembolism (HR 3.16; P=0.04).
Both oral anticoagulant (HR 0.32) and parenteral anticoagulant (HR 0.39) use reduced the risk for thromboembolism (all P<0.001). After adjustment, parenteral anticoagulant use had a borderline significant effect on both thromboembolism and bleeding events (HR 0.36; P=0.053), but significantly reduced the risk for the composite outcome of thromboembolism, bleeding events, and mortality (HR 0.70; P=0.02).
- Guo Y. Risk factors for systemic and venous thromboembolism, mortality and bleeding risk in 1125 patients with COVID-19: relationship to anticoagulation status. COVID and Cardiovascular Disease session, ESC Congress 2020, 30 Aug.
Posted on
Previous Article
« The Yale COVID-19 Cardiovascular Registry Next Article
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations »
« The Yale COVID-19 Cardiovascular Registry Next Article
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations »
Table of Contents: ESC 2020
Featured articles
2020 ESC Clinical Practice Guidelines
2020 Atrial Fibrillation Guidelines
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
2020 Adult Congenital Heart Disease Guidelines
Hot Line Presentations
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy
Reduced cardiovascular outcomes with early rhythm control
Trimetazidine after successful PCI not associated with fewer cardiac events
POPular TAVI: Aspirin-only antiplatelet strategy?
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Antihypertensives also reduce CV risk in people with normal blood pressure
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Drug initiation strategy not associated with increased use of oral anticoagulants
Restrictive blood transfusion non-inferior and cost-effective strategy
Late-Breaking Science
Increased mortality with colchicine in patients with ACS
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins
Antisense ANGPTL3 lowers triglycerides
Reduced progression of coronary atherosclerosis with icosapent ethyl
Digoxin improves symptoms in stable patients with permanent AF
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
COVID and Cardiovascular Disease
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials
Related Articles
November 5, 2020
2020 Adult Congenital Heart Disease Guidelines
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com